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Angiotensin II receptor blockade prevents acute renal sodium
retention induced by low levels of orthostatic stress
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Angiotensin II receptor blockade prevents acute renal sodium
retention induced by low levels of orthostatic stress.
Background. Depending on its magnitude, lower body neg-
ative pressure (LBNP) has been shown to induce a progressive
activation of neurohormonal, renal tubular, and renal hemo-
dynamic responses, thereby mimicking the renal responses
observed in clinical conditions characterized by a low effec-
tive arterial volume such as congestive heart failure. Our ob-
jective was to evaluate the impact of angiotensin II receptor
blockade with candesartan on the renal hemodynamic and uri-
nary excretory responses to a progressive orthostatic stress in
normal subjects.
Methods. Twenty healthy men were submitted to three levels
of LBNP (0, −10, and −20 mbar or 0, −7.5, and −15 mm Hg)
for 1 hour according to a crossover design with a minimum of
2 days between each level of LBNP. Ten subjects were randomly
allocated to receive a placebo and ten others were treated with
candesartan 16 mg orally for 10 days before and during the
three levels of LBNP. Systemic and renal hemodynamics, renal
sodium excretions, and the hormonal response were measured
hourly before, during, and for 2 hours after LBNP.
Results. During placebo, LBNP induced no change in sys-
temic and renal hemodynamics, but sodium excretion decreased
dose dependently with higher levels of LBNP. At −20 mbar, cu-
mulative 3-hour sodium balance was negative at –2.3±2.3 mmol
(mean ± SEM). With candesartan, mean blood pressure de-
creased (76 ± 1 mm Hg vs. 83 ± 3 mm Hg, candesartan vs.
placebo, P < 0.05) and renal plasma flow increased (858 ±
52 mL/min vs. 639 ± 36 mL/min, candesartan vs. placebo, P <
0.05). Glomerular filtration rate (GFR) was not significantly
higher with candesartan (127 ± 7 mL/min in placebo vs. 144 ±
12 mL/min in candesartan). No significant decrease in sodium
and water excretion was found during LBNP in candesartan-
treated subjects. At –20 mbar, the 3-hour cumulative sodium
excretion was + 4.6 ± 1.4 mmol in the candesartan group (P =
0.02 vs. placebo).
Conclusion. Selective blockade of angiotensin II type 1 (AT1)
receptors with candesartan increases renal blood flow and pre-
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vents the antinatriuresis during sustained lower body negative
pressure despite a modest decrease in blood pressure. These
results thus provide interesting insights into potential benefits
of AT1 receptor blockade in sodium-retaining states such as
congestive heart failure.
Chronic sodium-retaining edema-forming states such
as heart failure, the nephrotic syndrome, and hepatic cir-
rhosis are characterized by avid renal sodium and water
retention, which have been attributed to a low effective
arterial volume [1]. These disease states feature circula-
tory and volume control abnormalities characterized by
an activation of several neurohormonal systems, includ-
ing sympathetic nerve activity and the renin-angiotensin-
aldosterone and the vasopressin systems. These hormonal
systems influence renal function through their actions on
renal hemodynamics and water and electrolytes transport
across tubular cells [2].
In patients with heart failure, the renal response to
the low effective arterial volume is characterized by a
marked sodium retention, which leads to an undesirable
vicious circle contributing to a further deterioration of
the disease [3]. Blockade of the renin-angiotensin system
with angiotensin-converting enzyme (ACE) inhibitors or
selective angiotensin II receptor antagonists has been
shown to reduce the morbidity and mortality in patients
with congestive heart failure [4–7]. The beneficial effects
of these agents in heart failure have been attributed to the
reductions in preload and afterload as well as to the ame-
lioration of the hormonal profile both factors improving
cardiac output.
In heart failure, blockers of the renin-angiotensin sys-
tem could also lead to a clinical improvement through
a direct effect on renal function, independently of their
ability to modulate cardiac function. Indeed, ACE in-
hibitors as well as angiotensin II antagonists have been
shown to increase urinary sodium excretion in normoten-
sive and hypertensive subjects [8]. Blockers of the renin-
angiotensin system have also been found to improve
the ability to excrete acute and chronic sodium loads in
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animal models of congestive heart failure [9, 10]. The
purpose of the present study was to evaluate the clin-
ical impact of angiotensin II receptor blockade on the
renal hemodynamic and excretory responses to a pro-
gressive orthostatic stress in normotensive subjects. To
test this hypothesis, we have used the model of sustained
lower body negative pressure in normotensive subjects
pretreated randomly either with a placebo or with the
angiotensin II receptor antagonist candesartan. We have
shown previously that the application of a 1-hour lower
body negative pressure (LBNP) step-wise stimulates the
sympathetic nervous system and the renin-angiotensin
system leading to a decrease in urinary sodium and wa-
ter excretion before any changes in renal blood flow and
glomerular filtration rate (GFR) are observed [11]. Thus,
this model enables to mimic in normal subjects the hemo-
dynamic conditions to which the kidneys are exposed dur-
ing a progressive reduction of cardiac preload leading to
an activation of both the sympathetic nervous system and
the renin-angiotensin system.
METHODS
Twenty healthy normotensive subjects without any
clinical history of vasovagal syncope, orthostatic hypoten-
sion, clinical or laboratory evidence of heart, liver, kid-
ney, and endocrine diseases were included in this study.
Their mean age was 24.2 years (range 20 to 31 years).
Their mean height was 176 cm (range 166 to 189 cm) and
mean weight 73.3 kg (range 55 to 88 kg). A full medical
history and a complete physical examination, including
an orthostatic test, were performed before inclusion. The
protocol was approved by the local hospital ethical com-
mittee, and written informed consent was obtained from
each subject.
Study design
This was a randomized double-blind parallel group
(placebo vs. candesartan) study. Each subject was ini-
tially randomized to receive either 16 mg of candesartan
once a day or a placebo for 14 days (from day 1 to day
14). On days 10, 12, and 14 of the treatment, each volun-
teer was investigated before, during, and after stimulation
with one of three levels of LBNP (0, −10, and −20 mbar)
for 1 hour according to a triple crossover design. The –10
and 20 mbar values correspond to −7.5 and −15 mm Hg.
Each LBNP study day was separated by 48 hours and
subjects remained on treatment. The dose of candesar-
tan 16 mg or placebo was given orally every morning
at 8:00 a.m. The control phase (0 mbar) was randomized
within each sequence and the lower level of LBNP was al-
ways tested before the higher level. All subjects received a
fixed sodium diet (130 mmol sodium/day) provided by the
hospital from day 6 to day 14. Water intake was allowed
ad libitum. A series of 24-hour urine collections were per-
formed on days 8, 9, 11, and 13 to monitor the compliance
to the diet and to evaluate the baseline sodium, potas-
sium, and creatinine excretions. Subjects were asked to
refrain from smoking and drinking caffeine-containing
and alcoholic beverages from day 8 to day 14.
After an overnight fast, the volunteers were installed
in supine position during each whole study day, except for
voiding. An infusion of inulin and para-aminohippurate
(PAH) was started to measure GFR and renal plasma
flow (RPF). A light breakfast and an oral water load of
5 mL/kg were ingested before 8.00 a.m. Subsequently,
subjects received a fixed amount of water (150 mL/hour)
to maintain a stable urine output. After 3 hours of equili-
bration (T-240 to T-60), the study days were divided into
1 hour of baseline (T-60 to T0), 1 hour of LBNP (T0 to
T60) and 2 hours of recovery (R1 and R2) (T60 to T120
and T120 to T180). LBNP was applied with subjects in
the supine position in a solid plexiglas box sealed tightly
around the iliac crests, below the level of the kidneys.
A footplate was inserted in the box to prevent inward
movement of the volunteers. The 1-hour LBNP was not
interrupted to allow subjects to void.
Vital signs (blood pressure, heart rate) were recorded
using an automated monitor placed on the left arm (Life-
sign Monitor; WelchAllyn, Skaneateles Falls, NY, USA).
Measurements were done every 5 minutes from time
T-30 to T120 and every 15 minutes from T-120 to T-30
and T120 to T180. Urine was collected hourly through-
out the study to measure urine output, urinary electrolyte
excretion (sodium, potassium, endogenous trace lithium,
and uric acid) and to evaluate the changes in GFR and
RPF. The same parameters were measured hourly in the
plasma. Blood was collected on times T0, T60, and T120
for the measurements of plasma norepinephrine, aldos-
terone, and plasma renin activity (PRA).
Analytic methods
Urinary and plasma sodium and potassium were
measured by flame photometry (IL-943) (Instrumen-
tation Laboratory, Milan, Italy) and creatinine by the
picric acid method (Cobas-Mira; Roche AG, Basel,
Switzerland). Plasma and urinary inulin and PAH were
determined by photometry (Autoanalyzer II-Technicon;
Bran & Luebbe, Norderstedt, Germany). Endogenous
trace lithium was measured by atomic absorption spec-
trophotometry. This method, which does not necessitate
the administration of lithium, has been validated in sev-
eral previous clinical studies [12–15]. PRA [16], plasma
aldosterone [17], and plasma catecholamines [18] were
determined as described previously.
Urinary electrolytes excretion rate was calculated as
Ux · V (lmol/min) and clearances (mL/min) using the
standard formula Cx = Ux · V/Px where Ux and Px are the
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Table 1. Blood pressure and heart rate responses to lower body negative pressure (LBNP) during candesartan and placebo
LBNP 0 LBNP-10 LBNP-20
Baseline LBNP Recovery Baseline LBNP Recovery Baseline LBNP Recovery
Systolic blood pressure mm Hg
Placebo (N = 10) 114 ± 3 114 ± 3 117 ± 2 117 ± 4 121 ± 2 120 ± 3 113 ± 4 114 ± 2 116 ± 3
Candesartan (N = 10) 111 ± 2 115 ± 3 112 ± 2 109 ± 2a 111 ± 1b 111 ± 1a 107 ± 1 109 ± 2 110 ± 2
Diastolic blood pressure mm Hg
Placebo (N = 10) 65 ± 2 67 ± 3 69 ± 20 66 ± 3 71 ± 2c 70 ± 2 64 ± 2 68 ± 3d 69 ± 2
Candesartan (N = 10) 61 ± 2 63 ± 2 62 ± 2a 60 ± 10a 63 ± 2b,c 63 ± 1a 59 ± 1 62 ± 2d 61 ± 2a
Mean blood pressure mm Hg
Placebo (N = 10) 82 ± 2 82 ± 3 85 ± 2 83 ± 3 87 ± 2 86 ± 2 80 ± 3 83 ± 2 85 ± 2
Candesartan (N = 10) 78 ± 2 81 ± 2 78 ± 1a 76 ± 1b 79 ± 1b 79 ± 1b 75 ± 1 78 ± 2 77 ± 2a
Heat rate beats/min
Placebo (N = 10) 61 ± 3 56 ± 3d 57 ± 3 64 ± 4 60 ± 3d 59 ± 4 64 ± 3 60 ± 3d 57 ± 3
Candesartan (N = 10) 60 ± 2 59 ± 3 57 ± 3 61 ± 3 59 ± 3 56 ± 2 60 ± 3 59 ± 3 56 ± 3
Values are mean ± SEM.
aP < 0.05; bP < 0.01 candesartan vs. placebo during same period; cP < 0.05; dP < 0.01 LBNP vs. baseline.
urine and plasma concentrations of x and V is the urine
flow rate in mL/min. Filtration fraction was calculated by
dividing the GFR by the RPF. Renal vascular resistances
were calculated as mean blood pressure divided by the
renal blood flow, this latter being calculated from renal
plasma flow and hematocrit.
Statistics
All results are expressed as means ± SEM. Within
group analysis were performed using a one-way analy-
sis of variance (ANOVA) analysis followed by a Dunnett
test comparing the LBNP period to the baseline period
and the two recovery periods (R1 and R2). Intergroup
comparisons were analyzed using a Student t test except
for the analysis of cumulated sodium excretion were the
two groups were compared using the Mann-Whitney test.
Values with a P < 0.05 were considered as statistically
significant.
RESULTS
All volunteers completed the study (ten in each group).
The two levels of LBNP were well tolerated with no
syncope nor presyncopal signs and symptoms observed
throughout the study. Screening characteristics (age,
height, weight, systolic blood pressure, diastolic blood
pressure, and pulse) were similar for the two groups.
Twenty-four–hour urinary sodium excretion before and
between study days was similar in the placebo group
(112 ± 6 mmol/day) and in the candesartan (110 ±
7 mmol/day).
Systemic and renal hemodynamic responses to LBNP
At baseline, the heart rate was similar in both groups
whereas systolic and diastolic blood pressures were gen-
erally lower in the candesartan group (Table 1). During
LBNP and the recovery periods, no significant change
in systolic blood pressure was observed. In contrast,
diastolic blood pressure increased significantly during
LBNP at –10 and –20 mbar. Heart rate decreased
during LBNP but the changes were similar in the three
levels of LBNP.
As shown in Figure 1, the RPF was significantly higher
in the candesartan group than in the placebo group and
the GFR was slightly but not significantly higher in the
candesartan group. The GFR, the RPF and the renal vas-
cular resistance did not change throughout the study in
the placebo group. In contrast, the renal vascular resis-
tance increased (from 0.047 ± 0.003 mm Hg/mL/min to
0.057 ± 0.004 mm Hg/mL/min, P < 0.05) and the RPF
decreased (from 909 ± 61 mL/min to 746 ± 46 mL/min,
P < 0.05) during the LBNP period at –20 mbar in the
candesartan group. The fall in RPF at –20 mbar aver-
aged −17 ± 3% in the candesartan and −9 ± 5% in the
placebo group (P = NS). Consequently the filtration frac-
tion rose significantly during this period (from 16.2% ±
0.8% to 19.0% ± 1.1%). Yet, at the end of the −20 mbar
LBNP period, RPF was still higher in the candesartan
group than in the control group.
Neurohormonal responses during the LBNP
and recovery periods
The hormonal response to LBNP is presented in
Figure 2. At baseline, the hormone profile was similar in
the two groups except for PRA, which, as expected, was
higher in the candesartan group. Aldosterone was slightly
but not significantly lower in the candesartan group.
During LBNP, no change in plasma norepinephrine lev-
els was found in either groups at 0 and –10 mbar. At
–20 mbar an increase in norepinephrine was found in
both groups but the change did not reach the statistical
significance. PRA and aldosterone levels increased as the
negative pressures became stronger only in the placebo
group.
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Fig. 1. Effects of three levels of lower body
negative pressure (LBNP) on glomerular fil-
tration rate (GFR) and renal plasma flow
(RPF) in normotensive subjects who received
either candesartan 16 mg/day (dash lines) or
a placebo (solid lines) for 10 days. LBNP-10
and LBNP-20 indicate, respectively, –10 mbar
(−7.5 mmHg) and −20 mbar (−15 mm Hg) of
LBNP. LBNP was applied from 0 to 60 min-
utes. ∗P < 0.05; ∗∗P < 0.01 candesartan vs.
placebo at the same time; †P < 0.05 time 0 vs.
time 60 minutes. Values are means ± SEM.
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Fig. 2. Effects of three levels of lower body
negative pressure (LBNP) on plasma renin
activity (PRA) and plasma aldosterone and
plasma norepinephrine levels in normoten-
sive subjects who received either candesar-
tan 16 mg/day () or a placebo () for
10 days. LBNP-10 and LBNP-20 indicate, re-
spectively, −10 mbar (−7.5 mm Hg) and −20
mbar (−15 mm Hg) of LBNP. ∗P < 0.05; ∗∗P <
0.01 candesartan vs. placebo at the same time;
†P < 0.05; ††P < 0.01 vs. LBNP period.
Renal tubular response to LBNP
The changes in urinary water and electrolytes excre-
tion are presented in Table 2. In the placebo group, the
changes in urine output and electrolyte excretion were
the most pronounced during the –20 mbar LBNP pe-
riod when the suction on the limbs was stronger. The
LBNP-induced changes were characterized by a decrease
in urine output and sodium excretion and a fall in lithium
clearance suggesting a decrease in the proximal reab-
sorption of sodium. The decrease in potassium was also
slightly more pronounced at –20 mbar than at the two
other levels of LBNP. In the placebo group, sodium
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Table 2. Renal tubular response to lower body negative pressure (LBNP) in subjects receiving either a placebo or candesartan
LBNP T0 LBNP T10 LBNP T20
Baseline LBNP Recovery Baseline LBNP Recovery Baseline LBNP Recovery
UV mL/min
Placebo (N = 10) 2.90 ± 0.44 2.48 ± 0.32 2.88 ± 0.44 2.70 ± 0.38 2.55 ± 0.33 2.69 ± 0.43 2.91 ± 0.46 2.21 ± 0.33 2.37 ± 0.28
Candesartan 3.02 ± 0.41 3.50 ± 0.73 2.91 ± 0.37 2.49 ± 0.46 3.12 ± 0.38 3.36 ± 0.41 2.72 ± 0.45 2.30 ± 0.31 3.6 ± 0.29a
(N = 10)
UNaV lmol/min
Placebo (N = 10) 102 ± 12 84 ± 11 95 ± 11 89 ± 15 74 ± 12 93 ± 13 107 ± 20 70 ± 8b 104 ± 14
Candesartan 103 ± 23 93 ± 30 95 ± 11 85 ± 12 72 ± 11 113 ± 13c 95 ± 15 93 ± 18 119 ± 16d
(N = 10)
FENa %
Placebo (N = 10) 0.59 ± 0.07 0.52 ± 0.09 0.54 ± 0.07 0.53 ± 0.1 0.40 ± 0.07 0.51 ± 0.06 0.58 ± 0.09 0.42 ± 0.05b 0.59 ± 0.19c
Candesartan 0.49 ± 0.08 0.42 ± 0.09 0.51 ± 0.09 0.44 ± 0.08 0.35 ± 0.06 0.54 ± 0.07c 0.45 ± 0.05 0.47 ± 0.06 0.56 ± 0.06d
(N = 10)
UKV lmol/min
Placebo (N = 10) 96 ± 15 92 ± 11 70 ± 6 99 ± 13 93 ± 13 75 ± 9c 96 ± 9 83 ± 9 74 ± 7
Candesartan 96 ± 15 103 ± 15 71 ± 10d 98 ± 9 100 ± 11 71 ± 12c 91 ± 9 96 ± 10 75 ± 9d
(N = 10)
ClLi mL/min
Placebo (N = 10) 24.1 ± 2.5 25.2 ± 2.1 23.4 ± 1.5 27.3 ± 2.1 26.8 ± 2.6 25.8 ± 1.8 30.0 ± 2.5 22.3 ± 2.2b 23.6 ± 1.5
Candesartan 31.1 ± 2.7 28.0 ± 2.1 26.0 ± 1.8 31.8 ± 2.2 29.7 ± 1.9 30.0 ± 2.6 29.4 ± 1.2 26.1 ± 1.7 27.0 ± 2.2
(N = 10)
Values are mean ± SEM. Abbreviations are: UV, urine output; UNaV, sodium excretion; FENa, fractional excretion of sodium, UKV, potassium excretion; ClLi,
lithium clearance.
aP < 0.01 candesartan vs. placebo during same period; bP < 0.05 vs. baseline; cP < 0.01; dP < 0.05 LBNP vs. recovery period.
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Fig. 3. Effects of three levels of lower body negative pressure (LBNP) on cumulative urinary sodium excretion in normotensive subjects who
received either candesartan 16 mg/day (dash lines) or a placebo (solid lines) for 10 days. LBNP-10 and LBNP-20 indicate, respectively, −10 mbar
(−7.5 mm Hg) and −20 mbar (−15 mm Hg) of LBNP. ∗P ≤ 0.05; ∗∗P ≤ 0.01 vs. time 0.
excretion came back to the baseline during the first recov-
ery period whereas the effect of LBNP on urine flow rate
and lithium clearance persisted until the second recovery
period.
In the candesartan group, a nonsignificant decrease in
urine flow rate was also observed during the –20 mbar
LBNP period. However, no significant decrease in uri-
nary sodium and potassium excretions and endogenous
lithium clearance were found during LBNP in sub-
jects receiving candesartan. More interestingly, marked
increases in urine output and sodium excretion were
observed during the first and second recovery periods,
suggesting a rebound effect as soon as the LBNP was re-
moved. This rebound effect was strongest at –20 mbar
but was also present at –10 mbar. Figure 3 shows the cu-
mulative sodium excretion during the LBNP and the two
recovery periods in the two groups. The figure clearly
shows that subjects receiving candesartan maintain their
ability to excrete sodium at all levels of LBNP, whereas
in the control group, LBNP induces a level-dependent
decrease in cumulative sodium excretion. At –20 mbar,
the cumulative sodium excretion was significantly greater
under candesartan than under placebo (P = 0.02).
DISCUSSION
The purpose of the present study was to characterize
the effects of angiotensin II receptor blockade on the
renal response to a sustained orthostatic stress in men.
Our results show that candesartan lowers blood pressure
and increases RPF in normal subjects. Angiotensin II re-
ceptor blockade also induced a greater renal hemody-
namic response to orthostatic stress leading to a greater
decrease in renal plasma flow at a LBNP of –20 mbar
(−15 mm Hg). However, despite the decrease in renal
perfusion, subjects receiving the angiotensin II recep-
tor antagonist maintain their capacity to excrete sodium
during the orthostatic stress as candesartan reversed the
antinatriuretic response of the placebo into a natriuretic
response.
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Several previous studies have demonstrated in normal
subjects that low levels of LBNP (below −20 mm Hg) do
not affect renal hemodynamics, whereas the application
of a more prolonged and/or more intense LBNP lead-
ing to an unloading of both arterial and cardiopulmonary
baroreceptors produce a decline in GFR and RPF [19–
22]. In accordance with these earlier observations, no sig-
nificant change in renal hemodynamics was found during
LBNP in the placebo group. In contrast, a significant fall
in RPF and an increase in renal vascular resistance were
observed at –20 mbar (−15 mm Hg) in subjects receiv-
ing candesartan. Our experiment suggests that the renal
hemodynamic response to LBNP leading to a decrease in
renal perfusion is shifted to lower levels of LBNP when
the renin-angiotensin system is blocked resulting in an
inability to actively compensate for the orthostatic stress.
This could be due to an increased sensitivity to the stim-
ulation of efferent renal sympathetic nerve activity or to
the activation of other vasoconstrictor systems such as va-
sopressin or endothelin even though angiotensin II type
1 (AT1) receptor blockers have been found to decrease
sympathetic nerve activity in the kidney [23]. Such an
increased sensitivity is in line with earlier findings in an-
imal models in which blockade of the renin-angiotensin
cascade resulted in an increased vascular responsiveness
to sympathetic and vasopressin stimulation in order to
maintain blood pressure and organ perfusion [24]. Our
observations are also partially in accordance with the re-
cent report from Frank et al [22] who found a decrease in
RPF in a group of subjects treated with eprosartan, with
no change in GFR at –15 mm Hg. However, they did find
a decrease in RPF in the control group, which we did not
observe in the present as well as in previous studies at
similar levels of LBNP. The difference between the two
studies was the duration of the stimulation (30 minutes
in the study by Frank et al vs. 60 minutes in our study)
and a possible difference in the kinetics of the two drugs,
eprosartan being an AT1 antagonist with a shorter dura-
tion of action than candesartan. It has also been suggested
that eprosartan has a more pronounced effect on sympa-
thetic nerve activity than other angiotensin II receptor
antagonists [25]. This could also contribute to explain the
difference between the two studies.
Although RPF decreased during LBNP at –20 mbar,
renal perfusion remained adequate during angiotensin II
receptor blockade because candesartan increased RPF
at baseline. Thus, even at the end of the –20 mbar period
RPF was higher in the candesartan than in the placebo
group. This favorable hemodynamic effect of candesar-
tan is in accordance with previous studies, which have
demonstrated that angiotensin II receptor blockade leads
to a renal vasodilatation in humans [22] or restoration
of normal RPF in asymptomatic heart failure patients
[8].The candesartan-induced slight but nonsignificant in-
crease in GFR in normotensive subjects is more of a sur-
prise but candesartan has been found to increase GFR in
animal models [26–28] as well as in hypertensive patients
at the dose of 16 mg [29–31]. In other studies, however,
no change in GFR was found after administration of can-
desartan [32, 33].
The major observation of this study is that sodium
excretion is maintained during LBNP despite the tran-
sient decrease in RPF and is even increased during the
recovery period in the candesartan group. Thus, during
the 3 hours of investigations, the cumulative sodium ex-
cretion was significantly enhanced with the administra-
tion of candesartan. In the control group, the decrease
in sodium and water excretion observed at –20 mbar
(−15 mm Hg) was comparable to that obtained previ-
ously in the same experimental conditions. Interestingly,
the sodium retention was due mainly to an increased
reabsorption of sodium in the proximal tubule as indi-
cated by the significant fall in lithium clearance during
LBNP confirming thereby our initial finding [11]. Dur-
ing angiotensin II receptor blockade, neither the sodium
excretion nor the lithium clearance was affected by the
orthostatic stress. Initially, we had postulated that both
the renin-angiotensin and the sympathetic nervous sys-
tems contribute to the proximal sodium retention since
both systems have been reported to modulate sodium
transport in the proximal nephron [2]. The present find-
ings tend to confirm our hypothesis. To our knowledge,
only experiments in animal models have examined the
mechanism or the relative contribution of each system
to this favorable antinatriuretic effect and have found
that angiotensin II receptor blockade improves cardiac
baroreflex regulation of renal sympathetic nerve activ-
ity leading to an improved ability to excrete sodium
[10, 34].
In our experimental conditions, the natriuretic re-
sponse to angiotensin II receptor blockade was par-
ticularly pronounced during the two recovery periods.
The natriuresis was observed at –10 mbar as well as at
–20 mbar and was associated in both cases with a sig-
nificant decrease in plasma aldosterone levels. Hence, a
decreased reabsorption of sodium and water beyond the
proximal tubule may also contribute to the natriuresis at
least during the recovery phase. The early recovery period
is characterized by the shift of the volume pooled in the
extremities to the central circulation. Our data suggest
that blockade of the renin-angiotensin system improves
the ability of the kidneys to enhance water and sodium
excretion during this acute redistribution of volume. This
observation may be of clinical relevance as the recovery
period in a certain way mimics the redistribution of vol-
ume occurring in heart failure when patients go from the
standing to the supine position, during nighttime, for ex-
ample. Our observation would indicate that blockade of
the renin-angiotensin system also contributes to improve
patients suffering from heart failure by enhancing their
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ability to excrete water and sodium in supine position,
which has been shown in animal models of heart failure
[9].
Taken together, the results of the present study pro-
vide new insights into the role of the renin-angiotensin
system in regulating renal hemodynamics and sodium ex-
cretion during a mild orthostatic stress. More important,
they show that angiotensin II receptor blockade enables
to maintain renal sodium excretion when the orthostatic
stress is applied but also soon after its relieve. This find-
ing may contribute to explain the favorable impact of
interrupting the activity of the renin-angiotensin cascade
in patients with congestive heart failure in whom large
shifts of effective arterial volume occur depending on
the position.
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